Low urinary placental growth factor is a marker of pre-eclampsia  by Aggarwal, P.K. et al.
Low urinary placental growth factor is a marker
of pre-eclampsia
PK Aggarwal1, V Jain2, V Sakhuja1, SA Karumanchi3 and V Jha1
1Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India; 2Department of Obstetrics
and Gynecology, Postgraduate Institute of Medical Education and Research, Chandigarh, India and 3Renal Division, Department of
Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
Recent reports of increased serum levels of soluble fms-like
tyrosine kinase 1 (sFlt-1) and decreased levels of placental
growth factor (PlGF) suggest the key role of angiogenic
factors in development of pre-eclampsia. PlGF is excreted in
urine, and reduced urinary level has been suggested as a
marker of this condition as well as help in its prediction. We
measured urinary PlGF and creatinine values in 69 pregnant
women (35 with pre-eclampsia and 34 normotensive
controls). Over 70% patients had severe pre-eclampsia.
Compared to controls, the urinary PlGF and PlGF/creatinine
levels were significantly reduced in women with
pre-eclampsia. The hospital stay was longer and fetal
outcomes poorer in this group. Three normotensive women
who showed very low levels developed pre-eclampsia 2–6
weeks later. Reduced urinary PlGF level in a pregnant woman
is a marker of pre-eclampsia. The value of reduced urinary
PlGF levels in predicting pre-eclampsia in currently
normotensive pregnant women needs to be evaluated.
A simple predictive test is likely to be of value in the
developing countries.
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Pre-eclampsia, a pregnancy-specific syndrome characterized
by hypertension, proteinuria, and edema, is the leading cause
of maternal and perinatal morbidity and mortality.1,2 Pre-
eclampsia occurs only in the presence of placenta and its
resolution begins with the removal of placenta.
Recent investigations indicate that imbalance of angio-
genic factors may be responsible for at least two of pre-
eclampsia’s penotypes, hypertension, and proteinuria.3–10
Levels of circulatory soluble fms-like tyrosine kinase 1
(sFlt-1, also referred to as sVEGFR1) are increased, which
may then bind the proangiogenic vascular endothelial growth
factor (VEGF) and placental growth factor (PlGF), thereby
preventing their interaction with endothelial cell-surface
receptors.11 Infusion of adenoviruses transfected with sFlt-1
messenger ribonucleic acid in rats was followed by increased
circulating sFlt-1 levels and appearance of hypertension,
glomerular endotheliosis and proteinuria, the hallmarks of
pre-eclampsia.5,12 Elevated sFlt-1 and decreased free PlGF
and VEGF antedated the clinical signs.3,5,13 However, routine
measurement of these angiogenic mediators for ascertaining
the risk of pre-eclampsia could be difficult, and an
alternative, less invasive method more suited to routine
clinical use is required.
In contrast to the large (110 kDa) sFlt-1, PlGF (30 kDa)
and VEGF (45 kDa) cross the glomerular filtration barrier
and appear in urine. Podocytes and tubular cells produce
VEGF,14,15 and hence urinary VEGF cannot reflect circulating
VEGF levels. In contrast, urinary PlGF is derived entirely
from circulating blood and hence is likely to reflect the
circulating angiogenic state. We examined the utility of
reduced urinary PlGF as a marker of pre-eclampsia.
RESULTS
Table 1 shows the clinical characteristics of controls and those
with pre-eclampsia. There were no significant differences
between groups in the maternal age and gestational age at
the time of sampling. In all, 25 (71%) patients had severe
pre-eclampsia at presentation. The pre-eclampsia group
showed significantly lower urinary PlGF levels (18711.3 vs
205.87132.2 pg/ml, Po0.0001) and PlGF/creatinine ratio
(26.1716 vs 258.57130.5 pg/mg, Po0.0001). Figure 1
shows the PlGF and PlGF/creatinine ratios according to the
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gestational age. The mean PlGF levels were 15 and 10 times
lower before and after 32 weeks of gestation in the pre-
eclampsia group. PlGF normalized for urinary creatinine was
10- and 11-fold lower inp32- and 432-week gestational age
groups, respectively. PlGF values were lower in normotensive
pregnancies after 32 weeks of gestation (P¼ 0.048). In the
three normotensive women who developed pre-eclampsia
later, the urine PlGF (18.3, 16.4 and 21.2 pg/ml) and PlGF/
creatinine (14.6, 25.5 and 17.1 pg/mg) levels were similar to
those noted in those with pre-eclampsia. Post-hoc power
analysis showed that the study had 490% power to detect
difference between the different subgroups at 1% significance
level.
Among the pre-eclamptic women, reduced urinary PlGF
showed a significant correlation with elevated serum uric acid
(P¼ 0.031) and IUGR (P¼ 0.046), but there was no
correlation with systolic and diastolic blood pressures or
severity of proteinuria.
Of the 31 normotensive women, three delivered before 37
weeks of gestation. Two had small-for-gestational-age babies.
Out of the 35 cases with pre-eclampsia, 23 required delivery
within 24 h of presentation. Live infants of appropriate
weight for gestational age were delivered in 19 cases, 10 had
small-for-gestational-age infants and six ended in stillbirths.
Four infants required transfer to the neonatal intensive care
unit. Women with pre-eclampsia had a significantly longer
hospital stay (3.271.1 vs 0.970.3 days, Po0.01).
DISCUSSION
This prospective study confirms the hypothesis that urinary
concentrations of PlGF are significantly lower in pregnant
women with pre-eclampsia compared to normotensive
controls. The difference is maintained after normalization
for urinary creatinine concentrations. PlGF levels are lower in
normotensive pregnant women after 32 weeks of gestation;
hence, values in disease states should be compared with
normal values at the appropriate gestation age. We found that
urinary PlGF could differentiate women with pre-eclampsia
from normotensive controls in our population (women from
India), and confirmed the findings of Levine et al.10 Reduced
urinary PlGF level antedated the diagnosis of pre-eclampsia
by several weeks in their cohort, a phenomenon noted in
three cases in the present study too. These findings suggest
that this test may be useful for predicting this disorder. This
hypothesis needs to be tested prospectively in larger number
of cases. A limitation of this study was the lack of patient
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Figure 1 | Scattergram of (a) urinary PlGF and (b) urinary PlGF
after normalization for urinary creatinine in pregnant women
p32 weeks and after 32 weeks of gestation. Solid triangles
represent the normotensive control group and open triangles those
with pre-eclampsia. Horizontal lines in each group represent the
mean values.
Table 1 | Clinical parameters of normotensive pregnant women (controls) and those with preeclampsia
o32 weeks 432 weeks
Control (n=14) Pre-eclampsia (n=15) Control (n=17) Pre-eclampsia (n=20)
Period of gestation
Maternal age (years) 26.975.06 26.1374.22 26.5374.31 25.7574.18
Gestational age (weeks) 30.1670.89 30.2871.28 34.371.53 34.5671.18
Severe pre-eclampsia — 12 (80%) — 13 (65%)
Blood pressure (mmHg)
Systolic 114.775.54 170.2719.06* 110.6877.96 162.3712.62*
Diastolic 76.9373.78 107.6710.31* 78.4774.36 105.479.94*
Uric Acid (mg/dl) 3.4870.91 5.9771.38* 4.2271.02 6.6471.6*
*Po0.001 compared to control.
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groups with nonpre-eclamptic hypertension and intrauterine
growth retardation without pre-eclampsia. A recent study has
shown elevated urinary sFlt-1 levels in severe pre-eclampsia.16
However, the significance of this finding is questionable as it
was noted in patients who had disrupted glomerular
filtration barrier and heavy proteinuria.
VEGF and PlGF (angiogenic growth factors) are known to
promote vascular endothelial proliferation and differentia-
tion, cell migration, increase the vascular permeability,
inhibit apoptosis, and mediate endothelium-dependent
vasodilatation.17 Clark et al.18 first demonstrated that
placenta secreted sFlt-1, and postulated its role in regulation
of circulating VEGF during pregnancy. Maynard et al.5
confirmed the relationship between excess placental produc-
tion of sFlt-1 and endothelial dysfunction, hypertension, and
proteinuria of pre-eclampsia. Increased sFlt-1 possibly limits
the availability of VEGF and PlGF to cell-surface receptors,5,9
and these angiogenic proteins may serve as specific targets for
therapeutic intervention to restore the angiogenic balance. It
is therefore crucial to identify patients before clinical
manifestations appear, and determination of urinary PlGF
may serve this important role.
About 99% of all pregnancy-related deaths reported
worldwide occur in developing nations. Pre-eclampsia, along
with hemorrhage and infection, accounts for over 60% of
these deaths.19 There was no maternal death in the current
study despite having a high proportion of patients with
severe pre-eclampsia, possibly because they managed to reach
a tertiary care hospital. However, their hospital stay was
longer than controls. The poor fetal outcome in this group
reflects the lack of timely recognition of the disease,
culminating in development of complications before medical
attention could be sought. The Prevention of Maternal
Mortality Network has accepted the three-delay model, viz.
delay in decision to seek care, delay in arrival at the point of
care and delay in provision of adequate care, as the causes of
high mortality.20 The first two delays can be considerably
mitigated by a reliable, valid, and economical test that could
predict pre-eclampsia and prompt early referral. Being
noninvasive, urine test would be superior to one that requires
a blood draw. For it to be useful in remote areas of
developing countries, the technology needs to be simplified
to a point where the test does not require expensive
equipments and can be performed by personnel with limited
training.
MATERIALS AND METHODS
This prospective study was conducted at the Postgraduate Institute
of Medical Education and Research, a large tertiary care referral
hospital in north India. A total of 69 pregnant women (35
consecutive primigravid subjects with gestational ages ranging from
27 to 37 weeks referred with a diagnosis of pre-eclampsia and 34
normotensive controls) were enrolled. Pre-eclampsia was defined as
new-onset elevated blood pressure (X140/90 mmHg) and protei-
nuria X2þ by dipstick on two occasions at least 4 h apart. Anyone
with one of the following (blood pressureX160/110 mmHg on two
occasions 6 h apart, proteinuria X3þ on spot sample or 5 g/24 h,
intrauterine growth retardation, transaminitis, platelets o105/mm3,
headache, visual disturbances, symptoms of liver capsule distension,
oliguria, or hemolysis, elevated liver enzymes and low platelets
syndrome was classified as having severe pre-eclampsia. No subject
had eclampsia. Control subjects (pregnant women without hyper-
tension, proteinuria, or renal disease) were selected from the
Obstetrics outpatient population of the Institute after 1:1 matching
for age (within 1 year) and period of gestation (within 1 week).
No subject had a comorbid condition such as diabetes, asthma,
heart disease, kidney disease, autoimmune disease, urinary infec-
tion, or was a smoker. Published data10 were used to determine the
sample size. A minimum of six subjects were required in each
subgroup for a double-sided power of 0.9 at an alpha of 0.01. All
subjects who were approached consented to supply the urine
sample, and there were no refusals.
Blood pressure, urine protein and uric acid values were recorded.
Subjects were followed up until delivery. Babies with birth weight
below the 10th percentile of gestational age were classified as small-
for-age. Three patients, normotensive at the time of sample
collection, developed pre-eclampsia 3–6 weeks later and hence were
excluded from analysis.
Spot urine samples (10 ml) were collected in sterile containers,
centrifuged at 3000 g for 20 min at 41C and stored at 801C for
subsequent determination of the PlGF level. PlGF was measured
using a specific enzyme-linked immunosorbent assay kit according
to the manufacturer’s protocol (R&D Systems, Inc., Minneapolis,
MN, USA). The inter- and intra-assay coefficients of variation were
9.6 and 4.2%, respectively. Urinary creatinine was measured using a
commercial picric acid colorimetric assay (CRTN, Bayer Diagnostics
India Ltd, Baroda, India).
PlGF levels are expressed as raw values and after normalization
for urinary creatinine. Data are presented as mean7s.d. Subjects
were divided according to the period of gestation into two groups
(p32 and 432 weeks). Statistical analysis was carried out using
Statistical package for Social Sciences vs 12.0. Normality of
distribution was confirmed using a Q–Q plot. Groups were
compared using the unpaired Student’s ‘t’-test. Pearson’s correlation
was used to investigate the relationship between urinary PlGF and
other clinical variables. A P-value of o0.05 was considered
significant.
In conclusion, our results indicate that decreased urinary PlGF
level is associated with pre-eclampsia, and may antedate its clinical
manifestations. Its value in predicting the development of pre-
eclampsia needs to be tested in prospective studies. Urinary PlGF
holds promise as a noninvasive marker, but simpler methods for
detection of low urinary PlGF are required to make it useful in areas
with limited access to healthcare technology.
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